Ianalumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ianalumab comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Purpura, Thrombocytopenic, Idiopathic, and Lupus Nephritis. Most recent publication: Ianalumab plus Eltrombopag in Immune Thrombocytopenia., N Engl J Med, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
    Cuker A, Stauch T, Cooper N, et al. · N Engl J Med · 2026
    PubMed: PMID 41363800 · NCT05653219 (VAYHIT2) · Purpura, Thrombocytopenic, Idiopathic
  2. Targeting B Cells and Plasma Cells in Glomerular Disease.
    Ahmad SB, Jefferson JA · J Am Soc Nephrol · 2025
    PubMed: PMID 40465397 · NCT06711887 (SIRIUS-LN ext) · Lupus Nephritis

Publications by year

2025–2026: 2 publications.

2025
1
2026
1

Publications by indication

Purpura, Thrombocytopenic, Idiopathic (1)

Lupus Nephritis (1)

Publications by journal

  • N Engl J Med1 paper
  • J Am Soc Nephrol1 paper

All Ianalumab publications (2)

2026 (1 paper)

  1. Ianalumab plus Eltrombopag in Immune Thrombocytopenia.
    Cuker A, Stauch T, Cooper N, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41363800 · NCT05653219 (VAYHIT2) · Purpura, Thrombocytopenic, Idiopathic

2025 (1 paper)

  1. Targeting B Cells and Plasma Cells in Glomerular Disease.
    Ahmad SB, Jefferson JA · J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40465397 · NCT06711887 (SIRIUS-LN ext) · Lupus Nephritis

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Thu, 07 May 2026 20:07:13 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).